

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/045, 47/48, 31/70, 38/08, C07F 9/117	A2	(11) International Publication Number: WO 97/24111 (43) International Publication Date: 10 July 1997 (10.07.97)
(21) International Application Number: PCT/CA96/00870 (22) International Filing Date: 23 December 1996 (23.12.96) (30) Priority Data: 2,166,155 27 December 1995 (27.12.95) CA (71) Applicant (for all designated States except US): HYAL PHARMACEUTICAL CORPORATION [CA/CA]; 2425 Skymark Avenue, Mississauga, Ontario L4W 4Y6 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): TURLEY, Eva [CA/CA]; Apartment 107, 2287 Lakeshore Boulevard W., Grand Harbour, Toronto, Ontario M8V 3Y1 (CA). (74) Agent: HUGHES, Etigson; Suite 200, 175 Commerce Valley Drive West, Thornhill, Ontario L3T 7P6 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: HYALURONIC ACID RECEPTORS BINDING AGENTS AND THE USE THEREOF (57) Abstract A method for the treatment of, or prevention of a disease and/or condition in a patient which is treatable or preventable by receptor mediated treatment is provided, the method comprising the administration of an effective amount of a medicine and/or therapeutic agent with an effective amount of a binding agent (other than hyaluronan, a pharmaceutically acceptable salt thereof or other such forms of hyaluronic acid) which binding agent is mixed with the medicine and/or therapeutic agent and which binding agent binds at the site of the disease or condition with at least one of the group of binding domains selected from: (a) <u>RSHKTRSHH</u> {Single-Letter Code of Amino Acids} also identified as: <u>Arg-Ser-His-Lys-Thr-Arg-Ser-His-His</u> {Three-Letter Code of Amino Acids} also identified as: <u>CGC-TCG-CAC-AAG-ACC-AGG-TCG-CAC-CAC</u> {Another Code}; (b) <u>RPHFHKR</u> {Single Letter Code of Amino Acids} also identified as: <u>Arg-Pro-His-Phe-His-Lys-Arg</u> {Three-Letter Code of Amino Acids} also identified as <u>CGG-CCC-CAC-TTC-CAC-AAG-CGG</u> {Another Code}.		